A Discussion with Michael Proschan on Response-Adaptive Randomization

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/64/33/ba/6433ba0f-405d-81e6-bc82-4d4f04775f0a/mza_2622887070788468434.jpg/600x600bb.jpg

In the Interim...

Berry

30 episodes

1 week ago

A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.

All content for In the Interim... is the property of Berry and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

A Discussion with Michael Proschan on Response-Adaptive Randomization

In the Interim...

44 minutes

1 month ago

A Discussion with Michael Proschan on Response-Adaptive Randomization

In this episode of "In the Interim…", Dr. Scott Berry and NIH’s Dr. Michael Proschan conduct a detailed discussion from opposing viewpoints on response-adaptive randomization (RAR) in clinical trials. The discussion focuses on where they agree – on the positives and negatives of RAR, and where they disagree on its scientific use.

Key Highlights

Potential issues of using RAR: Potential temporal trends, unblinding, reduction in statistical efficiency in 2-arm trials
Potential benefits include improved statistical efficiency in multi-arm trials depending on the goals (e.g. dose-finding trials).
Potential unblinding of results in non-blinded trials and the need for operational excellence.
Ethical and Bayesian perspectives are considered, but emphasis remains empirical.

For more visit: https://www.berryconsultants.com/